TRPM1 and melanoma: Next, between August 6, 2021 and August 4, 2022, there was a substantial increase in detectable TRPM1 autoantibodies in the patient’s serum (Figures 3, 4), which preceded a melanoma relapse (leptomeningeal disease) in September 2022.